Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C17H18FN3S |
| Molecular Weight | 315.408 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN2C(C1)CN=C(C3=CC=CS3)C4=C2C=C(F)C=C4
InChI
InChIKey=ICHHTOMWWAMJQP-UHFFFAOYSA-N
InChI=1S/C17H18FN3S/c1-20-6-7-21-13(11-20)10-19-17(16-3-2-8-22-16)14-5-4-12(18)9-15(14)21/h2-5,8-9,13H,6-7,10-11H2,1H3
| Molecular Formula | C17H18FN3S |
| Molecular Weight | 315.408 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Timelotem is a benzodiazepine derivative patented by Kali-Chemie Pharma G.m.b.H. as an anesthetic agent. In preclinical models, Timelotem shows atypical antipsychotic activity. Timelotem antagonizes DL-2-amino-5-phosphonovaleric acid (AP-5)-induced sniffing and the body turns in rats. Further, Timelotem antagonized amphetamine-induced stereotyped behavior in rats but was found less active than haloperidol in this test.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:15:03 GMT 2023
by
admin
on
Sat Dec 16 10:15:03 GMT 2023
|
| Record UNII |
9B2BQO7LIL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
120106-97-0
Created by
admin on Sat Dec 16 10:15:03 GMT 2023 , Edited by admin on Sat Dec 16 10:15:03 GMT 2023
|
PRIMARY | |||
|
9B2BQO7LIL
Created by
admin on Sat Dec 16 10:15:03 GMT 2023 , Edited by admin on Sat Dec 16 10:15:03 GMT 2023
|
PRIMARY | |||
|
65844
Created by
admin on Sat Dec 16 10:15:03 GMT 2023 , Edited by admin on Sat Dec 16 10:15:03 GMT 2023
|
PRIMARY |